ArticleBiomedicines2023
Hyperpolarized Xenon-129: A New Tool to Assess Pulmonary Physiology in Patients with Pulmonary Fibrosis.
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Functional hyperpolarized gas magnetic resonance imaging of idiopathic pulmonary fibrosis: a systematic review.La Radiologia medica · 2026Pooled it
- Noble gases xenon and argon: from cellular signalling mechanisms to organoprotection and clinical applications.Journal of translational medicine · 2026Review
- Targeting the epithelium in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Endotypes and Phenotypes in ILD: Is It Time to Reclassify ILD by Risk Stratification?Biomedicines · 2025Article
- Hyperpolarized Xenon-129 MRI: Narrative Review of Clinical Studies, Testing, and Implementation of Advanced Pulmonary In Vivo Imaging and Its Diagnostic Applications.Diagnostics (Basel, Switzerland) · 2025Review
- Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
purposeThe existing tools to quantify lung function in interstitial lung diseases have significant limitations. Lung MRI imaging using inhaled hyperpolarized xenon-129 gas ( MATERIALS AND
methodsAfter institutional review board approval and informed consent and in compliance with HIPAA regulations, we performed chest CT, pulmonary function tests (PFTs), and
resultsThe
conclusionThe hyperpolarized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.